ORIC Pharmaceuticals has appointed Lori Friedman to serve as its chief scientific officer. Friedman is joining South San Francisco-based ORIC after 15 years at Roche’s Genentech unit, where she was most recently senior director of translational oncology. ORIC is developing therapies to treat drug-resistant cancers. The company’s lead program, ORIC-101, is in early-stage clinical testing.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
